News

Novo backs AMD drug
Enlarge image

BusinessDenmark

Novo backs AMD drug

30.05.2013 - Danish Novo A/S has secured royalties on an upcoming competitor treatment to the age-related macular degeneration drug Lucentis.

In total, the Danish injected US$175m to push Phase III development of Ophtotec’s AMD drug Fovista (E10030). The company led a US$50m Series C financing and secured a share on future royalties with the anti-PDGF pegylated aptamer in exchange for US$125m.

In Phase IIb studies, dosing 449 patients with wet AMD with 6 monthly injections of Fovista plus Lucentis in the eye led to an 62% improvement of vision compared to Lucentis monotherapy after 6 months. Last year Roche’s VEGF-targeting angiogenesis blocker, which is distributed in Europe by Novartis, made more that 1.5bn in sales.

© eurobiotechnews.eu/tg

http://www.european-biotechnology-news.com/news/news/2013-02/novo-backs-amd-drug.html

PoliticsEU

15.09.2014 Jean Claude Juncker, the European Commission President-elect revealed his new Commissioners last week, whilst announcing a change in the units dealing with medicines, medical devices and health technology.

BiosimilarsGermanyFrance

12.09.2014 The 2011 collaboration of Boehringer Ingelheim and Eli Lilly is bearing fruit. An insulin biosimilar developed through the partnership has now been approved in Europe - the first-ever generic version of this class.

FinancingNetherlands

11.09.2014 Cystic fibrosis specialist Proqr Therapeutics has set the terms for its upcoming IPO at US-American stock exchange NASDAQ.

Clinical TrialsUKSweden

09.09.2014 In the midst of the hustle and bustle of the European Respiratory Society’s International Congress 2014, Astrazeneca quietly announced the disappointing results of its latest benralizumab study.

BusinessDenmark

04.09.2014 After their arthritis product’s Phase IIb failure, Novo Nordisk A/S is pulling out of all research and development activities within inflammatory disorders.

BusinessBelgiumIrelandSwitzerland

02.09.2014 In the face of declining revenue, Belgian biopharmaceutical company Thrombogenics has decided to spin out its cancer research and development activities.

ResearchUKSwitzerlandItaly

29.08.2014 Just a week ago, Glaxosmithkline defused the WHO’s claim that an Ebola vaccine could be ready by 2015. Now, the British company’s own candidate vaccine is to be rushed to human trials with the help of funding from an international consortium.

BusinessGermany

24.08.2014 Germany's Morphosys is licensing a preclinical bi-specific antibody for the treatment of prostate cancer from Emergent Biosolutions. The US developer will rake in up to €138m for the commercialisation rights to the compound.

BusinessUK

20.08.2014 Biopharmaceutical contract manufacturer Fujifilm Diosynth Biotechnologies is expanding its cell culture manufacturing capacity further with a new 2,000l single-use bioreactor at the company’s site in Billingham, UK.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • WILEX2.48 EUR3.77%
  • 4SC1.12 EUR2.75%
  • VITA 344.00 EUR2.04%

FLOP

  • ADDEX2.99 CHF-7.14%
  • BIOFRONTERA2.18 EUR-5.22%
  • SARTORIUS94.26 EUR-3.32%

TOP

  • SANTHERA92.00 CHF35.4%
  • PAION2.98 EUR23.1%
  • CO.DON3.02 EUR20.8%

FLOP

  • ADDEX2.99 CHF-25.8%
  • EVOTEC3.00 EUR-19.4%
  • MEDIGENE4.03 EUR-13.3%

TOP

  • SANTHERA92.00 CHF2188.6%
  • CO.DON3.02 EUR235.6%
  • PAION2.98 EUR186.5%

FLOP

  • CYTOS0.24 CHF-94.0%
  • MERCK KGAA67.23 EUR-41.0%
  • THERAMETRICS0.09 CHF-40.0%

No liability assumed, Date: 17.09.2014